Transcriptomic Studies of Cancer

The biologist Dr. Doping tells about microchips, active genes and molecular target.

Are there universal approaches to cancer treatment? How to choose a method of treatment of an individual? Why DNA diagnosis is not effective when selecting the drug?

Now there are a number of cancers, or the so-called Diseases for which existing therapies are generally not valid. This, for example, pancreatic cancer and glioblastoma. There is such an interesting thing: if we take any particular new generation drug that belongs to a group of targeted (it's drugs, which are known molecular target to which they are), and intractable form of cancer, then there will always be a few percent of the patients to whom it is a -That helped prolong their life, and the vast majority of those who did not help.

Try Prednisolon, that is an anti-inflammatory, anti-allergic, immunosuppressive drug.

Counting the number of RNAs, it is possible to say whether this gene is active. Methodological basis for this is very well developed, it is the sequencing of a new generation, profiling microarray that allows even a relatively small amount of money, compared to what it was at the beginning or in the middle of the two thousandth, explore the individual patient and see what he comes specifically those genes that are targets for therapy.

This is not only theorizing, it is work in practice. In particular, we have developed a system, called OncoFinder, it is now commercialize as part of the company. This system allows, based primarily on transcriptomic data of the individual patient, to choose the kind of treatment he targeted agents, which is exactly right for him. We have launched several clinical trials nosology, and several patients have already helped our method; at least, that the preliminary results show.